Cargando…

L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease

Cell therapy is a promising treatment for Parkinson’s disease (PD), however clinical trials to date have shown relatively low survival and significant patient-to-patient variability. Glucagon Like Peptide-1 receptor (GLP-1R) agonists have potential neuroprotective effects on endogenous dopaminergic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elabi, Osama F., Davies, Jeffrey S., Lane, Emma L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618072/ https://www.ncbi.nlm.nih.gov/pubmed/34830228 http://dx.doi.org/10.3390/ijms222212346

Ejemplares similares

Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia
por: Elabi, Osama F., et al.
Publicado: (2023)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
por: Kuo, Tung-Tai, et al.
Publicado: (2023)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit
por: Paul, Gesine, et al.
Publicado: (2022)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012)

Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson’s disease and L-Dopa induced dyskinesia
por: Malave, Lauren, et al.
Publicado: (2021)

Impaired cognitive and motor function are coincident with l-DOPA-induced dyskinesia in a model of Parkinson’s disease
por: Lelos, Mariah J., et al.
Publicado: (2023)

3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA
por: Asanuma, Masato, et al.
Publicado: (2016)

The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients
por: Kukla, Aleksandra, et al.
Publicado: (2020)

Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopaminergic deficiency.
por: Jeon, B. S.
Publicado: (1997)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic Caenorhabditis elegans model of Parkinson’s disease
por: Manalo, Rafael Vincent M., et al.
Publicado: (2020)

Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
por: Rylander Ottosson, Daniella, et al.
Publicado: (2016)

Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson’s disease
por: Breger, Ludivine S., et al.
Publicado: (2017)

Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON l-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease
por: Vinuela, A., et al.
Publicado: (2008)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons
por: Radlicka, Anna, et al.
Publicado: (2021)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans.
por: Jauhar, S, et al.
Publicado: (2017)

Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication
por: Festini, Sara B., et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

No effect of a dopaminergic modulation fMRI task by amisulpride and L-DOPA on reward anticipation in healthy volunteers
por: Grimm, Oliver, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021)

Dopa Responsive Slow Orthostatic Tremor in Parkinson’s Disease
por: Lee, Suk Yoon, et al.
Publicado: (2011)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Correction: Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans
por: Jauhar, S., et al.
Publicado: (2018)

Correction: Regulation of dopaminergic function: An [(18)F]-DOPA PET apomorphine challenge study in humans
por: Jauhar, S, et al.
Publicado: (2019)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease
por: Peña, Edgar, et al.
Publicado: (2021)

Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
por: Wiesen, Tom, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lb2p3v9gsc9esgjbqj2l78c6q1